This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Myeloid malignancies: mutations, models and management
BMC Cancer Open Access 23 July 2012
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Haferlach C, Dicker F, Kohlmann A, Schindela S, Weiss T, Kern W et al. AML with CBFB–MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions. Leukemia 2010; 24: 1065–1069.
Suela J, Largo C, Ferreira B, Alvarez S, Robledo M, Gonzalez-Neira A et al. Neurofibromatosis 1, and Not TP53, seems to be the main target of chromosome 17 deletions in de novo acute myeloid leukemia. J Clin Oncol 2007; 25: 1151–1152.
Rucker FG, Bullinger L, Schwaenen C, Lipka DB, Wessendorf S, Frohling S et al. Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. J Clin Oncol 2006; 24: 3887–3894.
Yang G, Khalaf W, van de LL, Jansen JH, Gao M, Thompson MA et al. Transcriptional repression of the Neurofibromatosis-1 tumor suppressor by the t(8;21) fusion protein. Mol Cell Biol 2005; 25: 5869–5879.
Bacher U, Haferlach T, Schoch C, Kern W, Schnittger S . Implications of NRAS mutations in AML: a study of 2502 patients. Blood 2006; 107: 3847–3853.
Haferlach C, Bacher U, Haferlach T, Dicker F, Alpermann T, Kern W et al. The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML. Leukemia 2011; 25: 874–877.
Parkin B, Ouillette P, Wang Y, Liu Y, Wright W, Roulston D et al. NF1 inactivation in adult acute myelogenous leukemia. Clin Cancer Res 2010; 16: 4135–4147.
Yin B, Morgan K, Hasz DE, Mao Z, Largaespada DA . Nfl gene inactivation in acute myeloid leukemia cells confers cytarabine resistance through MAPK and mTOR pathways. Leukemia 2006; 20: 151–154.
Acknowledgements
We thank all clinicians for sending samples to our laboratory for diagnostic purposes, and for providing clinical information and follow-up data. In addition, we would like to thank all co-workers at the MLL (Munich Leukemia Laboratory) for approaching together many aspects in the field of leukemia diagnostics and research. Especially the technical assistance of Annika Eßer, Kathrin Stadler, Marita Staller and Melanie Zenger who performed FISH analyses is greatly appreciated. In addition, we are grateful for the data management support performed by Tamara Alpermann.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
CH, WK, SuS and TH are equity owners of, and AK, VG and SoS are employed by, the Munich Leukemia Laboratory.
Additional information
Supplementary Information accompanies the paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Haferlach, C., Grossmann, V., Kohlmann, A. et al. Deletion of the tumor-suppressor gene NF1 occurs in 5% of myeloid malignancies and is accompanied by a mutation in the remaining allele in half of the cases. Leukemia 26, 834–839 (2012). https://doi.org/10.1038/leu.2011.296
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2011.296
This article is cited by
-
NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome
Leukemia (2018)
-
Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable
International Journal of Hematology (2015)
-
Natural history of acute lymphoblastic leukemia in neurofibromatosis type 1 monozygotic twins
Leukemia (2013)
-
Myeloid malignancies: mutations, models and management
BMC Cancer (2012)